Moneycontrol PRO
HomeNewsIndiaChildren with comorbidities to get COVID-19 vaccine first: NK Arora

Children with comorbidities to get COVID-19 vaccine first: NK Arora

The Centre is working on how to identify kids who are at the highest risk of getting the severe disease and may require hospitalisation, Arora said.

October 04, 2021 / 11:34 IST
(Representative image)

Children with comorbidities will be prioritised for the COVID-19 vaccine once the paediatric drive commences, said National Technical Advisory Group on Immunisation (NTAGI) Chairperson Dr NK Arora.

"We are going to prioritise COVID-19 vaccination for children with comorbidities so that we immediately immunise them and the rest of
the population who are healthy can be immunised subsequently," Arora told news agency ANI.

Read | Zydus Cadila proposes Rs 1900 for three-dose COVID vaccine; Govt negotiating to bring it down

He said that the Centre is working on how to identify kids who are at the highest risk of getting the severe disease and may require hospitalisation.

Within the next couple of weeks, the list will be available in the public domain, he said, adding that arrangements are being made across the country so that children do not have to travel to places and ensure the vaccine is made available in all districts.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

India had in August approved Zydus Cadila's three-dose needle-free vaccine ZyCoV-D, making it the first vaccine to be administered in the age-group of 12 to 18, besides adults.

Also read: Zydus Cadila gets nod for phase 3 trial of two-dose regimen of ZyCoV-D

According to media reports, ZyCoV-D will be introduced in the nationwide COVID-19 vaccination drive by October 20. Different batches of ZyCoV-D are in the final round of quality checks at the country’s apex vaccine testing laboratory in Himachal Pradesh. The vaccine will be introduced in the country’s immunisation programme by October 15-20, according to the reports.

Talks are underway between the Centre and Zydus Cadila over the pricing of ZyCov-D after the pharma company reportedly proposed a price of Rs 1,900 for its three-dose jab.

Moneycontrol News
first published: Oct 4, 2021 11:34 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347